An International Trial to Evaluate the Efficacy and Safety of SABER®-Bupivacaine for Postoperative Pain Control in Patients Following Arthroscopic Shoulder Surgery
Primary Purpose
Postoperative Pain
Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
SABER-Bupivacaine Treatment 1a
Placebo SABER-Bupivacaine Treatment 1b
Bupivacaine HCl Treatment 1c
SABER-Bupivacaine Treatment 2a
Placebo SABER-Bupivacaine Treatment 2b
Bupivacaine HCl Treatment 2c
Sponsored by
About this trial
This is an interventional treatment trial for Postoperative Pain focused on measuring Post operative pain, Local anaesthesia, Postoperative pain after arthroscopic shoulder surgery
Eligibility Criteria
Inclusion Criteria:
- Subacromial impingement syndrome
- MRI with intact rotator cuff
- Patients suitable for general anaesthesia
Exclusion Criteria:
- Known major joint trauma, infection, avascular necrosis, chronic dislocation, inflammatory or degenerative glenohumeral arthropathy, glenohumeral arthritis, frozen shoulder or previous surgery of the affected shoulder
- Abnormal ECG
- Prolonged QT syndrome
- Current or regular use of analgesic medication for other indication(s)
Sites / Locations
- Nycomed Investigational Site
- Nycomed Investigational Site
- Nycomed Investigational Site
- Nycomed Investigational Site
- Nycomed Investigational Site
- Nycomed Investigational Site
- Nycomed Investigational Site
- Nycomed Investigational Site
- Nycomed Investigational Site
- Nycomed Investigational Site
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm Type
Experimental
Placebo Comparator
Active Comparator
Experimental
Placebo Comparator
Active Comparator
Arm Label
SABER-Bupivacaine Treatment 1a
Placebo SABER-Bupivacaine Treatment 1b
Bupivacaine HCl Treatment 1c
SABER-Bupivacaine Treatment 2a
Placebo SABER-Bupivacaine Treatment 2b
Bupivacaine HCl Treatment 2c
Arm Description
double-blind
double-blind
double-blind
double-blind
double-blind
double-blind
Outcomes
Primary Outcome Measures
Pain Intensity (PI)
Mean pain intensity on movement AUC (time-normalized AUC) during the period 0-3 days after surgery. Pain intensity was assessed with a standard 0 to 10 numeric rating scale (NRS), where no pain at all was rated as 0 and the worst pain imaginable was rated as 10. The AUC is computed for each patient using the standard trapezoidal rule and normalised by dividing by the time interval over which it is computed. This normalisation converts the AUC to the natural pain scale (NRS 0-10) to allow for better translation of the clinical treatment effect magnitude.
Supplemental Opioid Use
Cumulative IV morphine-equivalent dose of opioid rescue medication
Secondary Outcome Measures
Time to First Opioid Rescue Medication Usage
Opioid Related Side Effects
Opioid-related side effects were recorded 0-7 days after surgery. The Opioid-Related Symptom Distress Scale (OR-SDS) is a composite score computed from a questionnaire containing frequent opioid-related symptoms (Fatigue, Drowsiness, Inability to concentrate, Nausea, Dizziness, Constipation, Itching, Difficulty with urination, Confusion, Retching/vomiting). For each symptom, patients assigned integer scores to assess severity (none=0 to very severe=4), bothersomeness (none=0 to very much=5), and frequency (none=0 to almost constantly=4); patients reported number of Retching/vomiting episodes (none=0, 1-2 episodes=1, 3-4 episodes=2, 5-6 episodes=3, >6 episodes=4).
On each day (Day 0-7), the score for each symptom was the mean of the three component scores, and the OR-SDS score was the overall mean of the 10 symptom scores, (values from 0 to 4; larger outcomes are worse). The mean of the daily OR-SDS score from Day 0 to 7 gave the overall OR-SDS Score.
Full Information
NCT ID
NCT00993798
First Posted
October 9, 2009
Last Updated
May 13, 2021
Sponsor
Durect
Collaborators
Nycomed
1. Study Identification
Unique Protocol Identification Number
NCT00993798
Brief Title
An International Trial to Evaluate the Efficacy and Safety of SABER®-Bupivacaine for Postoperative Pain Control in Patients Following Arthroscopic Shoulder Surgery
Official Title
An International, Randomised, Double Blinded, Multi-centre, Active- and Placebo-controlled Dose Response Trial to Evaluate the Efficacy and Safety of SABER-Bupivacaine for Postoperative Pain Control in Patients Following Arthroscopic Shoulder Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
May 2021
Overall Recruitment Status
Completed
Study Start Date
April 2009 (undefined)
Primary Completion Date
June 2011 (Actual)
Study Completion Date
November 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Durect
Collaborators
Nycomed
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The objective is to identify the optimal dose of SABER-Bupivacaine for postoperative pain control in patients undergoing elective arthroscopic shoulder surgery on the basis of pharmacokinetics, efficacy and safety evaluations. The study duration consists of a screening period up to 14 days and a treatment period 14 days with a long term follow up visit at 6 months. The study will provide further data on safety.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postoperative Pain
Keywords
Post operative pain, Local anaesthesia, Postoperative pain after arthroscopic shoulder surgery
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
107 (Actual)
8. Arms, Groups, and Interventions
Arm Title
SABER-Bupivacaine Treatment 1a
Arm Type
Experimental
Arm Description
double-blind
Arm Title
Placebo SABER-Bupivacaine Treatment 1b
Arm Type
Placebo Comparator
Arm Description
double-blind
Arm Title
Bupivacaine HCl Treatment 1c
Arm Type
Active Comparator
Arm Description
double-blind
Arm Title
SABER-Bupivacaine Treatment 2a
Arm Type
Experimental
Arm Description
double-blind
Arm Title
Placebo SABER-Bupivacaine Treatment 2b
Arm Type
Placebo Comparator
Arm Description
double-blind
Arm Title
Bupivacaine HCl Treatment 2c
Arm Type
Active Comparator
Arm Description
double-blind
Intervention Type
Drug
Intervention Name(s)
SABER-Bupivacaine Treatment 1a
Other Intervention Name(s)
POSIMIR® bupivacaine solution
Intervention Description
5.0 ml
Intervention Type
Drug
Intervention Name(s)
Placebo SABER-Bupivacaine Treatment 1b
Intervention Description
5.0 ml
Intervention Type
Drug
Intervention Name(s)
Bupivacaine HCl Treatment 1c
Intervention Description
20.0 ml
Intervention Type
Drug
Intervention Name(s)
SABER-Bupivacaine Treatment 2a
Intervention Description
7.5 ml
Intervention Type
Drug
Intervention Name(s)
Placebo SABER-Bupivacaine Treatment 2b
Intervention Description
7.5 ml
Intervention Type
Drug
Intervention Name(s)
Bupivacaine HCl Treatment 2c
Intervention Description
20.0 ml
Primary Outcome Measure Information:
Title
Pain Intensity (PI)
Description
Mean pain intensity on movement AUC (time-normalized AUC) during the period 0-3 days after surgery. Pain intensity was assessed with a standard 0 to 10 numeric rating scale (NRS), where no pain at all was rated as 0 and the worst pain imaginable was rated as 10. The AUC is computed for each patient using the standard trapezoidal rule and normalised by dividing by the time interval over which it is computed. This normalisation converts the AUC to the natural pain scale (NRS 0-10) to allow for better translation of the clinical treatment effect magnitude.
Time Frame
0-3 days after surgery
Title
Supplemental Opioid Use
Description
Cumulative IV morphine-equivalent dose of opioid rescue medication
Time Frame
0-3 days after surgery
Secondary Outcome Measure Information:
Title
Time to First Opioid Rescue Medication Usage
Time Frame
0-14 days after surgery
Title
Opioid Related Side Effects
Description
Opioid-related side effects were recorded 0-7 days after surgery. The Opioid-Related Symptom Distress Scale (OR-SDS) is a composite score computed from a questionnaire containing frequent opioid-related symptoms (Fatigue, Drowsiness, Inability to concentrate, Nausea, Dizziness, Constipation, Itching, Difficulty with urination, Confusion, Retching/vomiting). For each symptom, patients assigned integer scores to assess severity (none=0 to very severe=4), bothersomeness (none=0 to very much=5), and frequency (none=0 to almost constantly=4); patients reported number of Retching/vomiting episodes (none=0, 1-2 episodes=1, 3-4 episodes=2, 5-6 episodes=3, >6 episodes=4).
On each day (Day 0-7), the score for each symptom was the mean of the three component scores, and the OR-SDS score was the overall mean of the 10 symptom scores, (values from 0 to 4; larger outcomes are worse). The mean of the daily OR-SDS score from Day 0 to 7 gave the overall OR-SDS Score.
Time Frame
0-7 days after surgery
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subacromial impingement syndrome
MRI with intact rotator cuff
Patients suitable for general anaesthesia
Exclusion Criteria:
Known major joint trauma, infection, avascular necrosis, chronic dislocation, inflammatory or degenerative glenohumeral arthropathy, glenohumeral arthritis, frozen shoulder or previous surgery of the affected shoulder
Abnormal ECG
Prolonged QT syndrome
Current or regular use of analgesic medication for other indication(s)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nycomed Clinical Trial Operations
Organizational Affiliation
Headquarters
Official's Role
Study Chair
Facility Information:
Facility Name
Nycomed Investigational Site
City
Graz
Country
Austria
Facility Name
Nycomed Investigational Site
City
Vienna
ZIP/Postal Code
1090
Country
Austria
Facility Name
Nycomed Investigational Site
City
Vienna
ZIP/Postal Code
1130
Country
Austria
Facility Name
Nycomed Investigational Site
City
Berlin
Country
Germany
Facility Name
Nycomed Investigational Site
City
Dresden
Country
Germany
Facility Name
Nycomed Investigational Site
City
Marburg
Country
Germany
Facility Name
Nycomed Investigational Site
City
Riga
Country
Latvia
Facility Name
Nycomed Investigational Site
City
Valmiera
Country
Latvia
Facility Name
Nycomed Investigational Site
City
Lodz
Country
Poland
Facility Name
Nycomed Investigational Site
City
Stockholm
Country
Sweden
12. IPD Sharing Statement
Learn more about this trial
An International Trial to Evaluate the Efficacy and Safety of SABER®-Bupivacaine for Postoperative Pain Control in Patients Following Arthroscopic Shoulder Surgery
We'll reach out to this number within 24 hrs